BofA analyst Tazeen Ahmad raised the firm’s price target on Incyte (INCY) to $87 from $86 and keeps a Buy rating on the shares. The firm ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, ...

Shares of Incyte Corp. rallied 4.13% to $59.22 Monday, on what proved to be an all-around favorable trading session for the ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte (INCY – Research Report) today and set a price target of ...

Shares of Incyte Corp. INCY slipped 1.25% to $57.73 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and ...

Incyte Corp. closed 34.28% below its 52-week high of $83.95, which the company achieved on November 8th.

After a legal decision delayed its entry last fall, Sun Pharma has received the all-clear to tap into the U.S. | After Sun ...

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast ...

Even inadvertent participation by a law clerk on a matter involving their future employer may call into question the court’s ...

A Federal Circuit panel looked likely to reverse a district court’s order blocking Sun Pharmaceutical Industries Ltd. from ...

Each RSU vests as to 25% of the shares subject to the RSU on each of the first four anniversaries of the vesting commencement date, subject to the employee's continued service with the Company on each ...

Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes novel medicines to address serious unmet medical ...